Desloratadine (Clarinex) and Desloratadine/Pseudoephedrine (Clarinex-D) prior authorization
Customize your policy alerts
Sign up for Health Net Policy CP CPA.123 alerts
Get alerted when Policy CP CPA.123 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for desloratadine (Clarinex) and desloratadine/pseudoephedrine (Clarinex-D 12 Hour) for commercial lines of business under Health Net/Centene Corporation.
Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less.
Revised policy/criteria section to also include generic desloratadine.
For brand requests, added redirection to generic.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.